MRSA Coverage Antibiotics for Cellulitis

Outpatient Oral Therapy for Uncomplicated Cellulitis

The Infectious Diseases Society of America recommends trimethoprim-sulfamethoxazole (TMP-SMX) 1-2 double-strength tablets twice daily or doxycycline 100 mg twice daily as first-line oral therapy for outpatient cellulitis requiring MRSA coverage 1
For purulent cellulitis, doxycycline 100 mg twice daily or minocycline 200 mg loading dose, then 100 mg twice daily are equally effective alternatives to TMP-SMX 1, 2
Clindamycin 300-450 mg three times daily should only be used if local MRSA resistance rates are below 10% due to concerns about inducible resistance 1, 3
TMP-SMX and tetracyclines (doxycycline/minocycline) have excellent MRSA coverage but poorly defined activity against β-hemolytic streptococci, which remain common cellulitis pathogens 1, 2
For non-purulent cellulitis, initial therapy should target β-hemolytic streptococci with a β-lactam (cephalexin 500 mg four times daily or dicloxacillin 500 mg four times daily) 1
Add MRSA coverage only if the patient fails to respond to β-lactam therapy within 48-72 hours, or if they present with systemic toxicity 1, 2

The Infectious Diseases Society of America recommends vancomycin 15-20 mg/kg IV every 8-12 hours as the gold standard for hospitalized patients requiring MRSA coverage 1, 3
Admit patients with high-risk features, including systemic signs of illness, rapidly progressive infection, multiple sites of infection, comorbidities, extremes of age, abscess in difficult-to-drain locations, or septic phlebitis 1, 2, 3
Alternative IV options when vancomycin cannot be used include linezolid 600 mg IV twice daily, daptomycin 4 mg/kg IV once daily, or clindamycin 600 mg IV three times daily if local resistance is low 1, 3

The key clinical question is whether to cover both MRSA and streptococci simultaneously, with purulent cellulitis with abscess/drainage being a primary concern for MRSA, and non-purulent typical cellulitis being more likely due to streptococci 1, 2
For severe cellulitis with systemic toxicity, cover both organisms empirically with clindamycin alone (if resistance <10%) or vancomycin plus piperacillin-tazobactam 1

Never use β-lactam antibiotics alone when MRSA is suspected or confirmed, as they have no activity against methicillin-resistant organisms 1
Never use rifampin as monotherapy or add it routinely to other antibiotics for skin infections, as resistance develops rapidly and there is no evidence of benefit 1, 2
Do not use clindamycin for serious infections if inducible resistance is detected on susceptibility testing, even though it may work for mild infections 1, 3

The Infectious Diseases Society of America recommends vancomycin (15-20 mg/kg IV every 8-12 hours) plus piperacillin-tazobactam for cellulitis requiring coverage of both MRSA and Streptococcus, or alternatively, clindamycin (600 mg PO three times daily) as monotherapy if local MRSA resistance rates are below 10% 4, 5

For patients with severe cellulitis and systemic signs, the IDSA specifically recommends vancomycin plus either piperacillin-tazobactam or imipenem-meropenem for severe infections requiring broad-spectrum coverage 4
Vancomycin 15-20 mg/kg IV every 8-12 hours is the cornerstone of therapy for severe cellulitis with systemic signs 4, 5, 6

The standard duration of treatment is 5 days, with extension if clinical improvement is not achieved, according to the Infectious Diseases Society of America 4
For uncomplicated cellulitis, treatment duration is 5-10 days 5, 6
For complicated infections, treatment duration is 7-14 days 5, 6

MRSA coverage is mandatory when cellulitis is associated with penetrating trauma, evidence of MRSA infection elsewhere or prior MRSA colonization, injection drug use, purulent drainage, or systemic inflammatory response syndrome (SIRS) 4, 5, 6

Beta-lactam antibiotics alone are inadequate for MRSA coverage and should never be used as monotherapy when MRSA is suspected 5
TMP-SMX or tetracyclines without a beta-lactam will miss streptococcal coverage, which remains the most common cause of typical cellulitis 5, 6
Failure to drain associated abscesses leads to treatment failure regardless of antibiotic choice 5, 6